값20242025TTM판매비·일반관리비—626 M—연구개발—1.61 B—영업 이익—1.06 B—비영업 수익, 합계———이자비용(자본화한 이자 차감 후)———이자비용을 제외한 비영업 수익———비정상 수입/지출———세전소득—1.2 B—지분법 손익———세금—241 M—비지배 지분———세후 기타 수익/비용———중단된 사업 부문 제외 순이익—963 M—중단된 사업———순이익—963 M—희석보정———우선배당———보통주주에게 귀속되는 희석 순이익———주당 순이익(기본 EPS)———희석 주당 순이익 (희석 EPS)———평균 발행주식수———희석주식수———EBITDA—-2.64 B—EBIT—-2.65 B—매출원가—238 M—기타 매출원가———감가상각 및 무형자산 상각 (현금흐름)—16 M—
Genmab A/S - American Depositary Shares
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US.